1- (4- bromophenylaminocarbonyl)- 4,5- diphenyl- 3- pyrazolidinone

a diphenylpyrazolidinone; cholecystokin antagonist; decreases midbrain dopamine unit activity; LY288513 and LY288512 are optical isomers of LlY262691

Also Known As:

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 11/18/1993 - "These results support the hypothesis that the selective CCK-B antagonist LY288513 may be an effective treatment for alleviating at least some benzodiazepine withdrawal symptoms in man."
2.	Schizophrenia (Dementia Praecox) 12/10/1991 - "Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity."
3.	Catalepsy 03/01/1996 - "However, LY288513 did not produce catalepsy. "

Related Drugs and Biologics

1.	Benzodiazepines
2.	Dopamine (Intropin)
3.	Cholecystokinin (Pancreozymin)